8-K: Oramed Reports Strong Q3 2025 Financials, Assets Up 42%

Oramed Pharmaceuticals announced strong unaudited financial results for the nine months ended September 30, 2025, driven by strategic investments and a 42% increase in total assets.

Summary

• Net income (pre-tax) of $65.0 million for the nine months ended September 30, 2025, a significant improvement from a net loss of $6.1 million in the same period last year.
• Completed full repayment of $100 million principal from Scilex Holding Company, with approximately $27 million received during the period.
• Basic earnings per share reached $1.30, and diluted earnings per share were $1.26.
• Total assets increased by 42% year-over-year, growing from $155.3 million to $220.5 million.
• Research and Development (R&D) expenses decreased from $4.9 million to $4.4 million.
• General and Administrative (G&A) expenses increased from $4.3 million to $5.0 million.
• The substantial improvement in net income was primarily attributed to realized cash returns from Scilex and significant unrealized fair-value gains from equity holdings in Alpha Tau Medical Ltd. and other investments.

Sentiment

Score: 8

Explanation: The company reported a significant turnaround from a net loss to a substantial net income, driven by successful investment returns and asset growth. This indicates strong financial health and strategic execution, despite a slight increase in G&A expenses.

Positives

• Net income (pre-tax) of $65.0 million, a substantial turnaround from a $6.1 million net loss in the prior year.
• Full repayment of $100 million principal from the strategic investment in Scilex has been completed.
• Strong basic earnings per share of $1.30 and diluted earnings per share of $1.26.
• Total assets grew 42% year-over-year, reaching $220.5 million, indicating robust balance sheet growth.
• Research and Development (R&D) expenses decreased to $4.4 million from $4.9 million, suggesting improved cost efficiency in R&D.
• Significant unrealized fair-value gains from equity holdings in Alpha Tau Medical Ltd. and other investments contributed positively to net income.

Negatives

• General and Administrative (G&A) expenses increased from $4.3 million to $5.0 million.

Risks

• Risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs.
• Difficulties or delays in obtaining regulatory approval for products.
• Competition from other pharmaceutical or biotechnology companies.
• Market volatility affecting the company's investment portfolio.
• Ability to realize expected returns from Scilex and other investments.
• Ability to identify and execute partnerships effectively.

Future Outlook

Oramed expects to continue pursuing strategic opportunities and advancing its oral drug delivery platform, leveraging its increased financial flexibility. The company also anticipates potential partnerships and dividend plans as part of its growth initiatives and diversified approach to creating shareholder value.

Management Comments

• "Our disciplined investment strategy is delivering strong results."
• "The complete $100 million cash repayment from Scilex, combined with substantial unrealized gains from our Alpha Tau position and other investments, has driven our $65 million net income and positioned us with greater financial flexibility to pursue strategic opportunities while advancing our oral drug delivery platform."

Industry Context

Oramed operates in the biotechnology and pharmaceutical sector, specializing in oral delivery solutions for drugs typically administered via injection. This focus addresses a significant market need for enhanced patient convenience and compliance. The company's strategy of combining its core drug delivery platform development with a disciplined investment portfolio (e.g., Scilex, Alpha Tau Medical) diversifies its revenue streams and financial stability, a less common but potentially effective approach for biotech firms facing long R&D cycles.

Stakeholder Impact

• Shareholders: Highly positive due to significant net income, strong EPS, substantial asset growth, and successful return on investment, potentially leading to increased share value and future dividends.
• Employees: Positive, as strong financial performance provides stability and resources for continued operations and development.
• Creditors: Positive, as a robust balance sheet with increased assets and net income improves the company's creditworthiness.

Next Steps

• Pursue strategic opportunities.
• Advance the oral drug delivery platform.
• Identify and execute partnerships.
• Potentially implement dividend plans.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance, transitioning from a net loss to a substantial net income of $65.0 million, primarily driven by successful strategic investments and a 42% increase in total assets. The full repayment of the $100 million Scilex investment significantly de-risks the balance sheet and provides substantial financial flexibility. With strong earnings per share and a clear strategy to advance its oral drug delivery platform while pursuing strategic opportunities, Oramed appears well-positioned for continued growth and shareholder value creation. The current results suggest a strong underlying business and effective capital allocation.

Keywords

Oramed Pharmaceuticals, ORMP, financial results, Q3 2025, net income, total assets, Scilex, Alpha Tau Medical, oral drug delivery, POD technology, biotechnology, pharmaceuticals, investment portfolio, earnings per share